We are live on
!
Find out more
Voloridge Investment Management Portfolio holdings
AUM
$25B
1-Year Est. Return
28.08%
This Fund
S&P 500
This Quarter
Est. Return
+6.27%
1 Year Est. Return
+28.08%
3 Year Est. Return
+85.2%
5 Year Est. Return
+73.43%
10 Year Est. Return
+582.16%
AUM
$17.9B
AUM Growth
-$597M
(-3.2%)
Cap. Flow
-$1.32B
Cap. Flow
% of AUM
-7.36%
Top 10 Holdings %
Top 10 Hldgs %
8.81%
Holding
1,709
New
345
Increased
450
Reduced
603
Closed
311
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$146M |
| 2 |
Apple
AAPL
|
+$129M |
| 3 |
Tesla
TSLA
|
+$110M |
| 4 |
Medtronic
MDT
|
+$104M |
| 5 |
Verizon
VZ
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$181M |
| 2 |
Microsoft
MSFT
|
+$177M |
| 3 |
Comcast
CMCSA
|
+$173M |
| 4 |
Adobe
ADBE
|
+$163M |
| 5 |
Broadcom
AVGO
|
+$157M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.34% |
| 2 | Healthcare | 14.31% |
| 3 | Consumer Discretionary | 12.9% |
| 4 | Industrials | 11.52% |
| 5 | Financials | 10.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Baxter International
BAX
$13.9B
| $8.54M | 0.05% |
+167,477
| New | +$9M |
|
|
SWTX
477
DELISTED
SpringWorks Therapeutics
SWTX
| $8.51M | 0.05% |
327,270
-123,724
| -27% | -$3.05M |
|
478
SSR Mining
SSRM
$6.63B
| $8.46M | 0.05% |
539,758
-344,382
| -39% | -$5.05M |
|
479
BioNTech
BNTX
$23.3B
| $8.43M | 0.05% |
56,145
+33,563
| +149% | +$5.16M |
|
480
Herc Holdings
HRI
$5.63B
| $8.43M | 0.05% |
64,079
-22,338
| -26% | -$2.74M |
|
|
NVRO
481
DELISTED
NEVRO CORP.
NVRO
| $8.43M | 0.05% |
212,877
+32,845
| +18% | +$1.37M |
|
482
Aon
AON
$74.7B
| $8.4M | 0.05% |
+27,985
| New | +$8.18M |
|
483
Travel + Leisure Co
TNL
$4.58B
| $8.36M | 0.05% |
229,756
+146,959
| +177% | +$5.51M |
|
484
CarGurus
CARG
$3.29B
| $8.28M | 0.05% |
591,092
+377,168
| +176% | +$5.17M |
|
485
Popular Inc
BPOP
$11.2B
| $8.28M | 0.05% |
124,849
+108,237
| +652% | +$7.53M |
|
|
RETA
486
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.28M | 0.05% |
217,847
-101,933
| -32% | -$3.51M |
|
|
SI
487
DELISTED
Silvergate Capital Corporation
SI
| $8.28M | 0.05% |
475,595
+185,841
| +64% | +$7.37M |
|
488
Immunocore
IMCR
$1.77B
| $8.26M | 0.05% |
144,734
+81,724
| +130% | +$4.6M |
|
489
Pan American Silver
PAAS
$22.1B
| $8.25M | 0.05% |
+504,902
| New | +$8.08M |
|
490
RLI Corp
RLI
$5.78B
| $8.22M | 0.05% |
125,204
+5,778
| +5% | +$359K |
|
491
TAL Education Group
TAL
$6.58B
| $8.14M | 0.05% |
1,155,095
+1,124,183
| +3,637% | +$6.23M |
|
492
DHT Holdings
DHT
$3.01B
| $8.1M | 0.05% |
+911,900
| New | +$8.3M |
|
493
Veracyte
VCYT
$3.59B
| $8.09M | 0.05% |
340,965
+7,741
| +2% | +$180K |
|
494
Pultegroup
PHM
$24.6B
| $8.09M | 0.05% |
177,639
-192,029
| -52% | -$8.09M |
|
495
CVS Health
CVS
$121B
| $8.08M | 0.05% |
86,740
-231,124
| -73% | -$22.3M |
|
496
Talos Energy
TALO
$2.59B
| $8.08M | 0.05% |
427,973
-180,503
| -30% | -$3.62M |
|
497
SLM Corp
SLM
$5.26B
| $8.08M | 0.05% |
486,628
-202,062
| -29% | -$3.31M |
|
498
Shift4
FOUR
$3.47B
| $8.06M | 0.04% |
144,175
-32,253
| -18% | -$1.52M |
|
499
Labcorp
LH
$26.2B
| $8.05M | 0.04% |
39,798
-10,118
| -20% | -$1.98M |
|
500
Ryan Specialty Holdings
RYAN
$11B
| $8.05M | 0.04% |
193,927
-27,773
| -13% | -$1.14M |
|
Similar funds
VAI
Voloridge Investment Management's Q4 2022 Portfolio in Review
As of Q4 2022, Voloridge Investment Management held 1,709 positions worth $17.9B, down 3.2% from $18.5B the previous quarter. Its ten largest holdings account for 8.8% of the portfolio.
Voloridge Investment Management withdrew a net $1.32B in Q4 2022, closing 311 positions and reducing 603 holdings. Its most notable exit was Berkshire Hathaway Class B, an estimated $181M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Voloridge Investment Management opened a new position in Edwards Lifesciences worth $142M.
- Voloridge Investment Management's largest Q4 2022 buy was Edwards Lifesciences: 1,898,822 shares worth $142M.
- Voloridge Investment Management added most to Tesla in Q4 2022, an estimated $110M increase.
- Voloridge Investment Management's biggest Q4 2022 reduction was Microsoft, cutting an estimated $177M.
- Voloridge Investment Management fully exited Berkshire Hathaway Class B in Q4 2022, selling an estimated $181M.
- Voloridge Investment Management's ten largest holdings make up 8.8% of its $17.9B portfolio in Q4 2022.
- Voloridge Investment Management opened 345 new positions and closed 311 in Q4 2022.
- Voloridge Investment Management's portfolio value fell 3.2% quarter-over-quarter to $17.9B.
Based on Voloridge Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.